Skip to main content
Top
Published in: Tumor Biology 2/2014

01-02-2014 | Research Article

miR-34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomere length in tumor stem cells

Authors: Ke Jin, Yonghua Xiang, Jing Tang, Guangchun Wu, Junwei Li, Huaichun Xiao, Chunwang Li, Yuxiang Chen, Jingfeng Zhao

Published in: Tumor Biology | Issue 2/2014

Login to get access

Abstract

miR-34a has been identified as a tumor suppressor in several tumors, but its involvement in gallbladder cancer (GBC) has not been reported. In this study, the miR-34a level and telomere length were measured in 77 gallbladder adenocarcinomas and 36 peritumoral tissues by real-time PCR. Forced miR-34a expression was established by an adenovirus carrying a miR-34a expression cassette. The colony-forming ability of isolated CD44+CD133+ GBC tumor stem-like cells was measured by matrigel colony assay. The xenograft tumor models were established by inoculating nude mice with CD44+CD133+cells. Results showed that significantly lower miR-34a expression and longer telomere length were observed in gallbladder adenocarcinoma tissues, which correlated with poor prognosis of GBC patients. Forced overexpression of miR-34a inhibited the colony-forming ability of CD44+CD133+ GBC tumor stem-like cells in vitro and xenograft tumor growth in vivo. Injection of Ad-miR-34a downregulated PNUTS expression and reduced telomere length in xenograft GBC tumor cells. In conclusion, miR-34a is a tumor suppressor in gallbladder cancer. Both low miR-34a expression and long telomere length are markers for poor prognosis of patients with gallbladder adenocarcinoma. Our study also suggests that the miR-34a gene could be a target for targeting therapy of GBC.
Literature
1.
go back to reference Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics 2008. CA Cancer J Clin. 2008;58:71–96.PubMedCrossRef Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics 2008. CA Cancer J Clin. 2008;58:71–96.PubMedCrossRef
2.
go back to reference Jayaraman S, Jarnagin WR. Management of gallbladder cancer. Gastroenterol Clin North Am. 2010;39:331–42.PubMedCrossRef Jayaraman S, Jarnagin WR. Management of gallbladder cancer. Gastroenterol Clin North Am. 2010;39:331–42.PubMedCrossRef
3.
go back to reference Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol. 2004;11:310–5.PubMedCrossRef Hawkins WG, DeMatteo RP, Jarnagin WR, Ben-Porat L, Blumgart LH, Fong Y. Jaundice predicts advanced disease and early mortality in patients with gallbladder cancer. Ann Surg Oncol. 2004;11:310–5.PubMedCrossRef
4.
go back to reference Ootani T, Shirai Y, Tsukada K, Muto T. Relationship between gallbladder carcinoma and the segmental type of adenomyomatosis of the gallbladder. Cancer. 1992;69:2647–52.PubMedCrossRef Ootani T, Shirai Y, Tsukada K, Muto T. Relationship between gallbladder carcinoma and the segmental type of adenomyomatosis of the gallbladder. Cancer. 1992;69:2647–52.PubMedCrossRef
5.
go back to reference Roa JC, Tapia O, Cakir A, Basturk O, Dursun N, Akdemir D, et al. Squamous cell and adenosquamous carcinomas of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas. Mod Pathol. 2011;24:1069–78.PubMedCrossRef Roa JC, Tapia O, Cakir A, Basturk O, Dursun N, Akdemir D, et al. Squamous cell and adenosquamous carcinomas of the gallbladder: clinicopathological analysis of 34 cases identified in 606 carcinomas. Mod Pathol. 2011;24:1069–78.PubMedCrossRef
7.
go back to reference Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20:515–24.PubMedCrossRef Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20:515–24.PubMedCrossRef
8.
go back to reference Bagga S, Pasquinelli AE. Identification and analysis of microRNAs. Genet Eng (N Y). 2006;27:1–20.CrossRef Bagga S, Pasquinelli AE. Identification and analysis of microRNAs. Genet Eng (N Y). 2006;27:1–20.CrossRef
9.
go back to reference Xiong J, Du Q, Liang Z. Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene. 2010;29:4980–8.PubMedCrossRef Xiong J, Du Q, Liang Z. Tumor-suppressive microRNA-22 inhibits the transcription of E-box-containing c-Myc target genes by silencing c-Myc binding protein. Oncogene. 2010;29:4980–8.PubMedCrossRef
10.
go back to reference Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007;26:731–43.PubMedCrossRef Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, et al. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell. 2007;26:731–43.PubMedCrossRef
11.
go back to reference Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007;6:1586–93.PubMedCrossRef Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle. 2007;6:1586–93.PubMedCrossRef
12.
go back to reference Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and microRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 2007;67:8433–8.PubMedCrossRef Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and microRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 2007;67:8433–8.PubMedCrossRef
13.
go back to reference Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007;17:1298–307.PubMedCrossRef Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol. 2007;17:1298–307.PubMedCrossRef
14.
go back to reference Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26:745–52.PubMedCentralPubMedCrossRef Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26:745–52.PubMedCentralPubMedCrossRef
15.
go back to reference Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 2008;7:2591–600.PubMedCrossRef Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle. 2008;7:2591–600.PubMedCrossRef
16.
go back to reference Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A, Heydt S, et al. MicroRNA-34a regulates cardiac ageing and function. Nature. 2013;495:107–10.PubMedCrossRef Boon RA, Iekushi K, Lechner S, Seeger T, Fischer A, Heydt S, et al. MicroRNA-34a regulates cardiac ageing and function. Nature. 2013;495:107–10.PubMedCrossRef
19.
go back to reference Hu Y, Ou Y, Wu K, Chen Y, Sun W. miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway. Tumour Biol. 2012;33:1863–70.PubMedCrossRef Hu Y, Ou Y, Wu K, Chen Y, Sun W. miR-143 inhibits the metastasis of pancreatic cancer and an associated signaling pathway. Tumour Biol. 2012;33:1863–70.PubMedCrossRef
20.
go back to reference Zhang X, Kon T, Wang H, Li F, Huang Q, Rabbani ZN, et al. Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res. 2004;64:8139–42.PubMedCrossRef Zhang X, Kon T, Wang H, Li F, Huang Q, Rabbani ZN, et al. Enhancement of hypoxia-induced tumor cell death in vitro and radiation therapy in vivo by use of small interfering RNA targeted to hypoxia-inducible factor-1alpha. Cancer Res. 2004;64:8139–42.PubMedCrossRef
21.
go back to reference Ogawa T, Saiki Y, Shiga K, Chen N, Fukushige S, Sunamura M, et al. miR-34a is downregulated in cis-diamminedichloroplatinum treated sinonasal squamous cell carcinoma patients with poor prognosis. Cancer Sci. 2012;103:1737–43.PubMedCrossRef Ogawa T, Saiki Y, Shiga K, Chen N, Fukushige S, Sunamura M, et al. miR-34a is downregulated in cis-diamminedichloroplatinum treated sinonasal squamous cell carcinoma patients with poor prognosis. Cancer Sci. 2012;103:1737–43.PubMedCrossRef
22.
go back to reference Gallardo E, Navarro A, Viñolas N, Marrades RM, Diaz T, Gel B, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009;30:1903–9.PubMedCrossRef Gallardo E, Navarro A, Viñolas N, Marrades RM, Diaz T, Gel B, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis. 2009;30:1903–9.PubMedCrossRef
23.
24.
go back to reference Eisenberg DTA. An evolutionaty review of human telomere biology: The thirty telomere hypothesis and notes on potential adaptive paternal effects. Am J Hum Biol. 2011;23:149–67.PubMedCrossRef Eisenberg DTA. An evolutionaty review of human telomere biology: The thirty telomere hypothesis and notes on potential adaptive paternal effects. Am J Hum Biol. 2011;23:149–67.PubMedCrossRef
25.
go back to reference Svenson U, Roos G. Telomere length as a biological marker in malignancy. Biochim Biophys Acta. 2009;1792:317–23.PubMedCrossRef Svenson U, Roos G. Telomere length as a biological marker in malignancy. Biochim Biophys Acta. 2009;1792:317–23.PubMedCrossRef
26.
go back to reference Bisofti M, Heaphy CM, Griffith JK. Telomeres: Prognostic markers for solid tumors. Int J Cancer. 2006;119:2255–60.CrossRef Bisofti M, Heaphy CM, Griffith JK. Telomeres: Prognostic markers for solid tumors. Int J Cancer. 2006;119:2255–60.CrossRef
27.
go back to reference Avigad S, Naumov I, Ohali A, Jeison M, Berco GH, Mardoukh J, et al. Short telomeres: a novel potential predictor of relapse in Ewing sarcoma. Clin Cancer Res. 2007;13:5777–83.PubMedCrossRef Avigad S, Naumov I, Ohali A, Jeison M, Berco GH, Mardoukh J, et al. Short telomeres: a novel potential predictor of relapse in Ewing sarcoma. Clin Cancer Res. 2007;13:5777–83.PubMedCrossRef
28.
go back to reference Shirotani Y, Hiyama K, Ishioka S, Inyaku K, Awaya Y, Yonehara S, et al. Alteration in length of telomeric repeats in lung cancer. Lung Cancer. 1994;11:29–41.PubMedCrossRef Shirotani Y, Hiyama K, Ishioka S, Inyaku K, Awaya Y, Yonehara S, et al. Alteration in length of telomeric repeats in lung cancer. Lung Cancer. 1994;11:29–41.PubMedCrossRef
29.
go back to reference Hirashima T, Komiya T, Nitta T, Takada Y, Kobayashi M, Masuda N, et al. Prognostic significance of telomeric repeat length alterations in pathological stage I–IIIA non-small cell lung cancer. Anticancer Res. 2000;20:2181–7.PubMed Hirashima T, Komiya T, Nitta T, Takada Y, Kobayashi M, Masuda N, et al. Prognostic significance of telomeric repeat length alterations in pathological stage I–IIIA non-small cell lung cancer. Anticancer Res. 2000;20:2181–7.PubMed
30.
go back to reference Frías C, García-Aranda C, De Juan C, Morán A, Ortega P, Gómez A, et al. Telomere shortening is associated with poor prognosis and telomerase activity correlates withDNArepair impairment in non-small cell lung cancer. Lung Cancer. 2008;60:416–25.PubMedCrossRef Frías C, García-Aranda C, De Juan C, Morán A, Ortega P, Gómez A, et al. Telomere shortening is associated with poor prognosis and telomerase activity correlates withDNArepair impairment in non-small cell lung cancer. Lung Cancer. 2008;60:416–25.PubMedCrossRef
31.
go back to reference Shi C, Tian R, Wang M, Wang X, Jiang J, Zhang Z, et al. CD44 + CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther. 2010;11:1182–90.CrossRef Shi C, Tian R, Wang M, Wang X, Jiang J, Zhang Z, et al. CD44 + CD133+ population exhibits cancer stem cell-like characteristics in human gallbladder carcinoma. Cancer Biol Ther. 2010;11:1182–90.CrossRef
32.
go back to reference Kim H, Lee OH, Xin H, Chen LY, Qin J, Chae HK, et al. TRF2 functions as a protein hub and regulates telomere maintenance by recognizing specific peptide motifs. Nat Struct Mol Biol. 2009;16:372–9.PubMedCrossRef Kim H, Lee OH, Xin H, Chen LY, Qin J, Chae HK, et al. TRF2 functions as a protein hub and regulates telomere maintenance by recognizing specific peptide motifs. Nat Struct Mol Biol. 2009;16:372–9.PubMedCrossRef
Metadata
Title
miR-34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomere length in tumor stem cells
Authors
Ke Jin
Yonghua Xiang
Jing Tang
Guangchun Wu
Junwei Li
Huaichun Xiao
Chunwang Li
Yuxiang Chen
Jingfeng Zhao
Publication date
01-02-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 2/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-1207-z

Other articles of this Issue 2/2014

Tumor Biology 2/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine